ISM7713

ISM7713 is a novel, orally bioavailable pan-KRAS inhibitor developed by Insilico Medicine for the treatment of solid tumors with KRAS alterations. It is designed to inhibit all major oncogenic KRAS variants, including G12D, G12V, G12C, and wild-type KRAS amplification, by binding to both the active (ON) and inactive (OFF) conformations of the protein. Preclinical data presented at AACR 2026 demonstrated that ISM7713 possesses picomolar to sub-nanomolar affinity for KRAS variants while selectively sparing HRAS and NRAS to mitigate potential toxicity. The compound has shown robust anti-tumor activity and tumor regression in multiple cell-derived xenograft (CDX) models and exhibits favorable pharmacokinetic properties across several animal species.